Over PhRMA’s Objections, US FDA To Study Accelerated Approval Disclosures in DTC Ads
Executive Summary
PhRMA argued the study is duplicative of previous project and lacks practical utility. Agency says it is replicating the prior study in a new patient population and testing additional versions of accelerated approval disclosure. Agency makes minor revisions to the study questionnaire.